All in all, Ptgfr was chosen to be the candidate for further analyses, as this GPCR gene (i) showed a significant increase in TAC vs. SHAM hearts both via bulk RNA sequencing and ddPCR, with a significant correlation between the two methods (Spearman R = 0.817, p = 0.011, Supplementary Figure S1); (ii) has a commercially available antagonist (AL-8810); and (iii) has not been described yet in the context of HF. The gene discussed is PTGFR; the disease is hydrops fetalis.